Thrombectomy in Patients Ineligible for iv tPA (THRILL)

Abstract

Rationale

A relevant proportion of patients with acute ischemic stroke are ineligible for intravenous thrombolysis with recombinant tissue plasminogen activator. Mechanical thrombectomy offers a treatment alternative for these patients; however, only few data are available on its safety and efficacy.

Aims and/or hypothesis

The aim of this study was to compare safety and efficacy of stent retrievers as device class with best medical care alone in acute stroke patients with large intracranial vessel occlusion in the anterior circulation who are not eligible for intravenous thrombolysis with recombinant tissue plasminogen activator up to eight-hours of symptom onset.

Design

‘Thrombectomy in patients ineligible for iv tPA’ is a prospective, open-label, blinded end-point, binational (Germany and Austria), two-arm, randomized, controlled, post-market study.

Study outcome(s)

Primary end-point is the modified Rankin Score shift analysis 90 days (±14) after stroke. Secondary end-points are excellent neurological outcomes (modified Rankin Score ≤ 1), good neurological outcomes (modified Rankin Score ≤ 2 or National Institutes of Health Stroke Scale improvement ≥ 10), difference between predicted infarct volume and actual core infarct volume (computed tomography or magnetic resonance imaging) at 30 (±6) h post-ictus, successful recanalization (thrombolysis in cerebral infarction score 2b or 3), functional health status 90 (±14) days after stroke (European Quality of Life-5 Dimensions) as well as common safety endpoints (adverse event, serious adverse event, symptomatic intracranial haemorrhage at 30 (±6) h, death, or dependency).

Discussion

Whether mechanical thrombectomy in patients with acute ischemic stroke who are not eligible for intravenous thrombolysis with recombinant tissue plasminogen activator improves clinical outcomes is unclear. ‘Thrombectomy in patients ineligible for iv tPA’ may change clinical practice by providing evidence of an effective and safe treatment for such patients.

Keywords

acute stroke therapy clinical trial intervention ischemic stroke treatment tPA

Get full access to this article

View all access options for this article.

References

European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457–507.

Del Zoppo

Saver

Jauch

Adams

Jr. , American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: A science advisory from the American Heart Association/American Stroke Association. Stroke 2009; 40: 2945–8.

Fiehler

Knudsen

Thomalla

. Vascular occlusion sites determine differences in lesion growth from early apparent diffusion coefficient lesion to final infarct. AJNR Am J Neuroradiol 2005; 26: 1056–61.

Riedel

Zimmermann

Jensen-Kondering

Stingele

Deuschl

Jansen

. The importance of size: Successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length. Stroke 2011; 42: 1775–7.

Penumbra Pivotal Stroke Trial Investigators. The penumbra pivotal stroke trial: Safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke 2009; 40: 2761–8.

Smith

Sung

Saver

. Mechanical thrombectomy for acute ischemic stroke: Final results of the Multi MERCI trial. Stroke 2008; 39: 1205–12.

Nogueira

Lutsep

Gupta

. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): A randomised trial. Lancet 2012; 380: 1231–40.

Saver

Jahan

Levy

. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): A randomised, parallel-group, non-inferiority trial. Lancet 2012; 380: 1241–9.

Broderick

Tomsick

Palesch

. Endovascular treatment for acute ischemic stroke. N Engl J Med 2013; 368: 2432–3.

10.

Ciccone

Valvassori

, SYNTHESIS Expansion Investigators. Endovascular treatment for acute ischemic stroke. N Engl J Med 2013; 368: 2433–4.

11.

Kidwell

Jahan

Saver

. Endovascular treatment for acute ischemic stroke. N Engl J Med 2013; 368: 2434–5.

12.

Berkhemer

Fransen

Beumer

. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015; 372: 11–20.

13.

Sulter

Steen

De Keyser

. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 1999; 30: 1538–41.

14.

Zaidat

Yoo

Khatri

. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: A consensus statement. Stroke 2013; 44: 2650–63.

15.

Saqqur

Tsivgoulis

Molina

. Design of a PROspective multi-national CLOTBUST collaboration on reperfusion therapies for stroke (CLOTBUST-PRO). Int J Stroke 2008; 3: 66–72.

16.

Saver

Gornbein

. Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. Neurology 2009; 72: 1310–5.

17.

Wahlgren

Ahmed

Davalos

. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): An observational study. Lancet 2007; 369: 275–82.

18.

Vahedi

Hofmeijer

Juettler

. Early decompressive surgery in malignant infarction of the middle cerebral artery: A pooled analysis of three randomised controlled trials. Lancet Neurol 2007; 6: 215–22.

19.

Lan

Gordon KK

Demets

. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659–63.